REG - Immupharma PLC - Directorate Change

ImmuPharmaAnnouncement

11/08/2023 12:17

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230811:nRSK1084Ja&default-theme=true

RNS Number : 1084J  Immupharma PLC  11 August 2023

 

11 August 2023

ImmuPharma PLC

("ImmuPharma" or the "Company")

BOARD STRENGTHENED AHEAD OF NEXT PHASE OF COMPANY PROGRESSION

ImmuPharma PLC (LSE:IMM),  the specialist drug discovery and development
company, provides notification of changes to its Board of Directors.

It has been a pivotal 2023 for ImmuPharma, specifically within its P140
autoimmune platform.

Most recently in June, the Company announced that, after receiving
comprehensive guidance from the Food & Drug Administration ("FDA") on the
new Phase 2/3 adaptive clinical trial protocol for the lead programme for the
treatment of patients with systemic lupus erythematosus ("SLE/Lupus"), it is
moving forward with the study, together with its US partner Avion.

Positive progress on the P140 platform was also announced in May for a second
high medical need disease, chronic idiopathic demyelinating polyneuropathy
("CIDP"). The Company received positive feedback from the FDA at a pre-IND
meeting for a late-stage Phase 2/3 adaptive clinical program in patients,
which is a further debilitating auto-immune condition within the Company's
P140 platform.

In parallel with advancements in the late-stage clinical developments, the
Company is also actively in discussions with a number of potential licensing
partners for programmes across the Company's development portfolio.

In order to align with the new phase of progress, the Company recognised the
need to add further skills and experience to the Board to ensure that we have
the requisite Board composition for the next stage of evolution of the
business.

We are therefore delighted to announce today the appointment of Dr Laurence
Reilly as Senior independent Non-Executive Director and Chair of the Audit
Committee. Dr Reilly brings extensive experience in managing late-stage
clinical programs through to approval, in addition to commercial and business
development experience.

 

He is currently Vice President of Research & Investments, working with
Royalty Pharma, a New York based life science investment company focussing on
acquisition of biopharmaceutical royalties and funding of innovation across
the biopharmaceutical industry.

 

Through his consulting practice (Acumen Life Science Investment Consulting) Dr
Reilly has provided strategic consulting and due-diligence services to biotech
companies, life science venture capital and private equity clients. He also
served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a
late-stage oncology biotech company. Prior to founding his consulting
practice, Dr Reilly served as Chief Scientific Officer and Vice President at
Avillion, a drug development company focused on the co-development and
financing of drug candidates, where he was responsible for clinical and
strategic oversight of co-development programs and partnering with both large
pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr Reilly
previously served as a Clinician - Clinical Development & Medical
Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

 

Dr Reilly earned his medical degree from the University of Liverpool Medical
School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth
University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in
Law from De Montfort University, U.K.

 

We are also extremely pleased to welcome Dr Sébastien Goudreau to the Board.

Dr Goudreau joined ImmuPharma in 2014 as research director and established the
research laboratories of Ureka Pharma (now ImmuPharma Biotech, the Company's
French subsidiary) in Bordeaux, being promoted in 2021 to Chief Executive
Officer of ImmuPharma Biotech. Notably, working directly with Dr Tim Franklin
(ImmuPharma COO), Dr Goudreau and his team are credited for the development
of, among others, the Company's anti-infective programmes,  BioAMB and
BioCin.

Dr Goudreau has also been a key contributor to the progression of the P140
autoimmune platform including the PK study, successfully concluded in 2022,
and supported the new protocol design of the Phase 2/3 adaptive clinical
studies for both Lupus and CIDP.

Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a
NSERC fellow before moving to Switzerland to conduct postdoctoral studies at
the ETH Zürich as an FRQNT fellow.

 

At this time, Dr Sanjeev Pandya, has informed the Board that he wishes to step
down from his Non-Executive Director position, in order to pursue a number of
other external opportunities.

 

All Board changes take place with immediate effect.

 

Commenting on the Board changes, Tim McCarthy, Chief Executive Officer said:

"I am delighted to welcome Laurence to the Board. His deep centred experience
of late-stage drug development, together with his international business
development expertise, will perfectly complement with and support the
executive management team and together will ensure that we have the essential
skills and knowledge required for the next stage of ImmuPharma's evolution.

I am also extremely pleased to welcome Sébastien to the Board. Having now
worked closely with Sébastien over the last 2 years and seen first-hand how
he has added invaluable insight and clinical direction within our drug
portfolio, his  appointment will be an extremely positive addition to the
Board.

We are now on a pivotal course for ImmuPharma. As a Board, we remain focused
on bringing our two key late stage P140 clinical assets in Lupus and CIDP
through their final clinical trials and to the market.

We also continue to concentrate on further commercial and partnering
opportunities and with these new Board appointments believe this may be
accelerated over the next period."

 

End

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

Additional information:

 

The following information is disclosed pursuant to Schedule Two paragraph (g)
of the AIM Rules for Companies:

 

Dr Sebastien Goudreau, aged 42, holds or has previously held the following
directorships:

 

 Current directorships and/or partnerships  Former directorships and/or partnerships (within the last five years):
 ImmuPharma France SA*                      N/A

 Ureka Pharma SAS*

 FindMolecule Inc.

 Pharmanoviq SAS

 

*an ImmuPharma group company

Dr Goudreau holds 150,000 shares & 1,150,000 options in the Company.

 

 

Dr Laurence Robert Reilly, aged 41, holds or has previously held the following
directorships:

 

 Current directorships and/or partnerships           Former directorships and/or partnerships (within the last five years):
 HEX Therapeutics LLP                                N/A

 Acumen Life Science Investment Consulting Limited

 

Dr Reilly holds no shares in the Company.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  + 44 (0) 207 152 4080

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 815 8880

 Patrick Claridge

 John Howes

 Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class
autophagy immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases that share the
same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma
(http://www.immupharma.co.uk) .co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOANKDBKDBKDKFD